Cost analysis of an intravenous to subcutaneous epoetin α conversion

American Journal of Nephrology

Volumn 38, Issue 6, 2014, Pages 496-500

  Wazny, Lori D ^a   Raymond, Colette B ^a   Sood, Amy R ^a   Eng, Amanda ^a   Verrelli, Mauro ^a  

^a HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Anemia drug therapy; Epoetin ; Erythropoietin administration dosage; Erythropoietin costs; Renal dialysis; Subcutaneous injections

Indexed keywords

FERRIC GLUCONATE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CACHEXIA; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; DRUG SUBSTITUTION; MEDICAL RECORD REVIEW;

ADMINISTRATION, INTRAVENOUS; ERYTHROPOIETIN; HEALTH CARE COSTS; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MANITOBA; RECOMBINANT PROTEINS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84893089827     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000357052     Document Type: Article

References (32)

1. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, et al: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998; 339: 578-583.
2. Besarab A, Reyes CM, Hornberger J: Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 439-446. (Pubitemid 34971270)
3. Thamer M, Zhang Y, Kaufman J, Stefanik K, Cotter DJ: Factors influencing route of administration for epoetin treatment among he-modialysis patients in the United States. Am J Kidney Dis 2006; 48: 77-87.
4. Besarab A: Optimizing anaemia management with subcutaneous administration of epoetin. Nephrol Dial Transplant 2005; 20(suppl 6):vi10-vi15.
5. Hynes DM, Stroupe KT, Kaufman JS, Reda DJ, Peterman A, Browning MM, et al: Adherence to guidelines for ESRD anemia management. Am J Kidney Dis 2006; 47: 455-461. (Pubitemid 43255179)
6. Tonelli M, Klarenbach S, Wiebe N, Shrive F, Hemmelgarn B, Manns B: Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation. Ottawa, Canadian Agency for Drugs and Technologies in Health, 2008, Technology Report 106, www.cadth.org (accessed: Nov 1, 2013).
7. Moist LM, Troyanov S, White CT, Wazny LD, Wilson JA, McFarlane P, et al: Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis 2013; 62: 860-873.
8. Macdougall IC, Roger SD, de Francisco A, Goldsmith DJ, Schellekens H, Ebbers H, et al: Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int 2012; 81: 727-732.
9. 2012 Annual report of the Dialysis Outcomes and Practice Patterns Study: Hemodialysis data 1997-2011. Ann Arbor, Arbor Research Collaborative for Health, 2012, www.dopps. org (accessed Nov 1, 2013).
10. DOPPS Practice Monitor. Ann Arbor, Arbor Research Collaborative for Health, 2013, www.dopps.org/dpm (accessed Nov 1, 2013).
11. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279-335, www.kdigo.org (accessed Nov 1, 2013).
12. De Schoenmakere G, Lameire N, Dhondt A, Van Loo A, Van der Goten J, Duym P, et al: The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). Nephrol Dial Transplant 1998; 13: 1770-1775. (Pubitemid 28306809)
13. Eprex (epoetin alfa) product monograph. Toronto, Janssen Inc., 2011.
14. Moist LM, Foley RN, Barrett BJ, Madore F, White CT, Klarenbach SW, et al: Clinical practice guidelines for evidence-based use of erythropoietic- stimulating agents. Kidney Int Suppl 2008; 110:S12-S18.
15. Madore F, White CT, Foley RN, Barrett BJ, Moist LM, Klarenbach SW, et al: Clinical practice guidelines for assessment and management of iron deficiency. Kidney Int Suppl 2008; 110:S7-S11.
16. Pussell BA, Walker R: Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration. Nephrology (Carlton) 2007; 12: 120-125. (Pubitemid 46426852)
17. Linde T, Furuland H, Wikstrom B: Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodi-alysis patients: results from a Swedish multi-centre survey. Scand J Urol Nephrol 2005; 39: 329-333. (Pubitemid 41499684)
18. Jacobs C, Horl WH, Macdougall IC, Valder-rabano F, Parrondo I, Abraham IL, et al: European best practice guidelines 9-13: anaemia management. Nephrol Dial Transplant 2000; 15(suppl):33-42.
19. McFarlane PA, Hillmer MP, Dacouris N: A change from subcutaneous to intravenous erythropoietin increases the cost of anemia therapy. Nephron Clin Pract 2007; 107:c90-c96. (Pubitemid 350073613)
20. Moist LM, Muirhead N, Wazny LD, Gallo KL, Heidenheim AP, House AA: Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis. Ann Phar-macother 2006; 40: 198-203. (Pubitemid 43269847)
21. Hynes DM, Stroupe KT, Greer JW, Reda DJ, Frankenfield DL, Kaufman JS, et al: Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med 2002; 112: 169-175.
22. Kaufman JS: Relationship of erythropoiesis-stimulating agent dose and responsiveness and adverse outcomes in CKD. Am J Kidney Dis 2011; 57: 661-663.
23. McCullough PA, Barnhart HX, Inrig JK, Red-dan D, Sapp S, Patel UD, et al: Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol 2013; 37: 549-558.
24. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876. (Pubitemid 39445919)
25. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084. (Pubitemid 44749316)
26. Levin A: Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 2007; 22: 309-312. (Pubitemid 46189866)
27. Wazny LD, Raymond CB, Do MK, Skwarchuk DE: Reduced drug costs from switching he-modialysis patients from epoetin alfa in mul-tidose vials to pre-filled syringes. CANNT J 2009; 19: 39-41.
28. Hingwala J, Diamond J, Tangri N, Bueti J, Rigatto C, Sood MM, et al: Underutilization of peritoneal dialysis: the role of the nephrol-ogist's referral pattern. Nephrol Dial Transplant 2013; 28: 732-740.
29. Raymond CB, Wazny LD, Vercaigne LM, Les-perance EM, Skwarchuk DE, Bernstein KN: Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios. CANNT J 2008; 18: 39-43.
30. Wazny LD, Raymond CB, Lesperance EM, Bernstein KN: Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodi-alysis patients achievable? Results from a provincial renal program. CANNT J 2008; 18: 36, 41, 44-50.
31. FDA Drug Safety Communication June 24, 2011: Modified dosing recommendations to improve the safe use of erythropoiesis-stimu-lating agents (ESAs) in chronic kidney disease. http://www.fda.gov/Drugs/DrugSafety/ucm259639. htm (accessed: Nov 1, 2013).
32. United States Renal Data System. USRDS 2012 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institute of Diabetes and Digestive and Kidney Diseases 2012, vol 2, chapt 10, www.usrds.org (accessed Nov 1, 2013).